BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA Zacks Equity Research Aug 12, 2026 Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.